Effective immediately, GeneGo will become part of the Healthcare & Science business of Thomson Reuters.
The acquisition enables Thomson Reuters to provide the pharmaceutical, biotechnology, and academic research communities with solutions that provide better understanding of the underlying mechanism of disease and potential therapies.
San Diego-based GeneGo’s scientific expertise and assets in biology-driven drug discovery complement the Thomson Reuters life sciences portfolio that covers drug pipeline competitive intelligence, patents, and chemistry.
Thomson Reuters executive vice president Jon Brett-Harris said that there is an increasing need for biology content, detailed disease insights, and analytics to support R&D productivity and to enable a more personalised approach to medicine.